Literature DB >> 8283077

The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin-hypersecreting neoplasm of the pancreas.

K Satoh1, T Sawai, T Shimosegawa, M Koizumi, T Yamazaki, F Mochizuki, T Toyota.   

Abstract

In order to clarify whether the detection of a point mutation in the c-Ki-ras gene at codon 12 in tumor tissues can assist in predicting the tumor's biological grade of malignancy, two types of tumors were investigated; one was called "carcinoma in the pancreatic head region," and the other was intraductal mucin-hypersecreting neoplasm of the pancreas (IMHN). Dot hybridization and a modified PCR technique developed by Haliassos et al. were employed. Among 16 cases of tumors in the pancreatic head region, the point mutation was detected with a high frequency only in pancreatic ductal cell carcinomas (five out of six cases, 83.3%), but was not detected in extrahepatic bile duct carcinomas (0/5) or in ampullary carcinomas (0/5). In pancreatic ductal cell carcinomas, no relation was found between the occurrence of the point mutation and the histological type of the tumor. Among 20 cases of IMHNs, the point mutation was found in 11 cases (55%). No relation was found between the occurrence of the mutation and the size of IMHNs. However, as the grade of cell atypia increased, the frequency of the mutation tended to become higher. These results suggest that detection of this point mutation might be useful for distinguishing pancreatic ductal cell carcinoma from those of other origins in the pancreatic head region, and for the determination of the histopathological grade of malignancy in IMHNs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8283077     DOI: 10.1007/BF02786119

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  23 in total

1.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

Authors:  V T Smit; A J Boot; A M Smits; G J Fleuren; C J Cornelisse; J L Bos
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

2.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

3.  "Ductectatic" mucinous cystadenoma and cystadenocarcinoma of the pancreas.

Authors:  Y Itai; K Ohhashi; H Nagai; Y Murakami; T Kokubo; K Makita; K Ohtomo
Journal:  Radiology       Date:  1986-12       Impact factor: 11.105

4.  Relation of pancreatic duct hyperplasia to carcinoma.

Authors:  S Kozuka; R Sassa; T Taki; K Masamoto; S Nagasawa; S Saga; K Hasegawa; M Takeuchi
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

Review 5.  The ras gene family and human carcinogenesis.

Authors:  J L Bos
Journal:  Mutat Res       Date:  1988-05       Impact factor: 2.433

6.  A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides.

Authors:  M Verlaan-de Vries; M E Bogaard; H van den Elst; J H van Boom; A J van der Eb; J L Bos
Journal:  Gene       Date:  1986       Impact factor: 3.688

7.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

Authors:  C Almoguera; D Shibata; K Forrester; J Martin; N Arnheim; M Perucho
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

8.  Mucinous ductal ectasia of the pancreas: a premalignant disease and a cause of obstructive pancreatitis.

Authors:  C Bastid; J P Bernard; H Sarles; M J Payan; J Sahel
Journal:  Pancreas       Date:  1991-01       Impact factor: 3.327

9.  High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.

Authors:  K Grünewald; J Lyons; A Fröhlich; H Feichtinger; R A Weger; G Schwab; J W Janssen; C R Bartram
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

10.  Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese.

Authors:  Y Nagata; M Abe; K Motoshima; E Nakayama; H Shiku
Journal:  Jpn J Cancer Res       Date:  1990-02
View more
  12 in total

Review 1.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

2.  High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN).

Authors:  Nir Lubezky; Menahem Ben-Haim; Sylvia Marmor; Eli Brazowsky; Gideon Rechavi; Joseph M Klausner; Yoram Cohen
Journal:  J Gastrointest Surg       Date:  2011-01-12       Impact factor: 3.452

3.  Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.

Authors:  Dai Mohri; Yoshinari Asaoka; Hideaki Ijichi; Koji Miyabayashi; Yotaro Kudo; Motoko Seto; Miki Ohta; Motohisa Tada; Yasuo Tanaka; Tsuneo Ikenoue; Keisuke Tateishi; Hiroyuki Isayama; Fumihiko Kanai; Noriyoshi Fukushima; Minoru Tada; Takao Kawabe; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2011-11-01       Impact factor: 7.527

4.  Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas.

Authors:  K Z'graggen; J A Rivera; C C Compton; M Pins; J Werner; C Fernández-del Castillo; D W Rattner; K B Lewandrowski; A K Rustgi; A L Warshaw
Journal:  Ann Surg       Date:  1997-10       Impact factor: 12.969

5.  BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Karl C Bruckman; Nancy T Ciau; Xiaojun Li; Margaret H Lauerman; Harold Frucht; John A Chabot; John D Allendorf; Helen E Remotti; Gloria H Su
Journal:  Cancer Lett       Date:  2006-11-09       Impact factor: 8.679

6.  PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Helen E Remotti; Werner Hohenberger; Gloria H Su
Journal:  Langenbecks Arch Surg       Date:  2008-02-21       Impact factor: 3.445

7.  Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells.

Authors:  Kennichi Satoh; Shin Hamada; Kenji Kimura; Atsushi Kanno; Morihisa Hirota; Jun Umino; Wataru Fujibuchi; Atsushi Masamune; Naoki Tanaka; Koh Miura; Shinichi Egawa; Fuyuhiko Motoi; Michiaki Unno; Barbara K Vonderhaar; Tooru Shimosegawa
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

8.  Does "clonal progression" relate to the development of intraductal papillary mucinous tumors of the pancreas?

Authors:  Keita Wada; Tadahiro Takada; Hideki Yasuda; Hodaka Amano; Masahiro Yoshida; Maki Sugimoto; Hiroshi Irie
Journal:  J Gastrointest Surg       Date:  2004 Mar-Apr       Impact factor: 3.452

9.  Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.

Authors:  F Sessa; E Solcia; C Capella; M Bonato; A Scarpa; G Zamboni; N S Pellegata; G N Ranzani; F Rickaert; G Klöppel
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

10.  Expression of MSX2 predicts malignancy of branch duct intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Kennichi Satoh; Shin Hamada; Atsushi Kanno; Morihisa Hirota; Jun Umino; Hiromichi Ito; Atsushi Masamune; Shinichi Egawa; Michiaki Unno; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2010-01-28       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.